Skip to main content
Figure 6 | Molecular Cancer

Figure 6

From: Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non–small-cell lung cancer xenograft models

Figure 6

Histomorphometric analyses of viable tumor burden and tumor blood vessel area in representative NSCLC xenografts treated with motesanib and/or cisplatin. Representative images and quantification of tumor blood vessel area (A) and viable tumor burden (B) from NCI-H358 xenografts treated with vehicle, motesanib 15 mg/kg BID, cisplatin 5 mg/kg QW, or motesanib plus cisplatin at the same dose and schedule. *P < 0.05 vs vehicle; †P < 0.05 vs vehicle and cisplatin monotherapy. Representative images and quantification of tumor blood vessel area (C) and viable tumor burden (D) from NCI-H1650 xenografts treated with vehicle, motesanib 15 mg/kg QD, cisplatin 4 mg/kg QW, or motesanib plus cisplatin at the same dose and schedule. *P < 0.0001 vs vehicle; †P < 0.0001 vs vehicle and cisplatin monotherapy; ‡P = 0.0039 vs vehicle. Data are expressed as mean ± SE (panel A, n = 6; panel B, n = 10; panel C, n = 10; panel D, n = 10). Bar, 100 μm (panels A and C) or 2 mm (panels B and D).

Back to article page

Molecular Cancer

ISSN: 1476-4598